We anticipate two potential applications of our findings: first, HDGC-like patients who test negative for CDH1 and CTNNA1 pathogenic variants, who by HDGC definition only have diffuse tumours, should be offered a broader cancer panel. This evidence concerns the gene CDH1 and cancer.